JINYU(SH:600201) Ge Long Hui·2026-01-09 06:11Core Viewpoint - The report from Kaiyuan Securities highlights that BioShares is a leading player in China's animal health sector, with a diverse range of over a hundred vaccines covering pigs, poultry, ruminants, and pets. The company is expected to see significant growth driven by its new vaccines, particularly the African swine fever vaccine, which is nearing market launch [1] Financial Projections - The company maintains its profit forecast for 2025 while raising the profit estimates for 2026 and 2027. The projected net profits for 2025, 2026, and 2027 are 188 million, 712 million, and 1.211 billion yuan respectively, with earnings per share (EPS) of 0.17, 0.64, and 1.09 yuan [1] - The previous profit forecasts for 2026 and 2027 were 352 million and 508 million yuan respectively [1] Valuation Metrics - The current price-to-earnings (PE) ratios for the company are projected to be 98.5, 25.9, and 15.3 for the years 2025, 2026, and 2027 respectively [1] Investment Rating - The company is expected to maintain strong growth momentum with the imminent global launch of its African swine fever vaccine, leading to a "buy" rating [1]